Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 2,462 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,462 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $156.30, for a total value of $384,810.60. Following the completion of the sale, the chief financial officer owned 98,114 shares of the company’s stock, valued at approximately $15,335,218.20. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

• On Friday, October 2nd, Adam Laponis sold 8,057 shares of Twist Bioscience stock. The shares were sold at an average price of $188.88, for a total value of $1,521,806.16.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $151.33 on Wednesday. The stock has a market capitalization of $9.49 billion, a price-to-earnings ratio of -68.17 and a beta of 2.19. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The stock’s 50 day moving average price is $146.38 and its two-hundred day moving average price is $98.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period last year, the business earned $0.33 EPS. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sivik Global Healthcare LLC bought a new position in shares of Twist Bioscience in the 3rd quarter worth $218,000. Fermata Advisors LLC bought a new stake in Twist Bioscience during the 3rd quarter valued at $243,000. GAMMA Investing LLC increased its stake in Twist Bioscience by 40.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,327 shares of the company’s stock valued at $256,000 after purchasing an additional 384 shares in the last quarter. Veracity Capital LLC bought a new stake in Twist Bioscience during the 3rd quarter valued at $726,000. Finally, QRG Capital Management Inc. acquired a new position in Twist Bioscience during the second quarter worth $277,000.

Analysts Set New Price Targets

TWST has been the subject of a number of research reports. BWS Financial restated a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Canaccord Genuity Group upped their price objective on shares of Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a report on Monday. UBS Group assumed coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective on the stock. Leerink Partners increased their price objective on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research note on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Twist Bioscience currently has an average rating of “Hold” and an average target price of $143.67.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.